{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-118241","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.306417+00:00","generated_at":"2026-06-08T04:07:37.528647+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Structure Therapeutics reports Q3 net loss of $23.9M, advances GSBR-1290 and forms Schrödinger collaboration","bullets":["Phase 1b study of GSBR-1290 showed up to 4.9% placebo-adjusted weight loss; no AE-related discontinuations.","Topline Phase 2a T2DM data expected December 2023; obesity cohort data H1 2024; global Phase 2b planned H2 2024.","Completed $300M private placement in October 2023; cash $205.4M at Sept 30, extending runway through 2026.","Collaboration with Schrödinger: up to $89M milestones plus low single-digit royalties on net sales.","Net loss $23.9M for Q3 2023 vs $12.4M in Q3 2022; R&D expenses increased to $17.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-118241","json":"https://secwatch.observer/filing/0001104659-23-118241.json","markdown":"https://secwatch.observer/filing/0001104659-23-118241.md","text":"https://secwatch.observer/filing/0001104659-23-118241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923118241/0001104659-23-118241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923118241/tm2329572d10_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:07:37.528647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e7b0f4587c05276466ab4f96eae094855383e12b","claim":"Structure Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, the Company issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923118241/0001104659-23-118241-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"46c143617e7a8912980b1f160205f8e1a4b6747e","claim":"Structure Therapeutics Inc. entered into Aconcagua-Schrödinger Agreement with Schrödinger, Inc. valued at up to an aggregate of $89.0 million (effective 2023-11-07).","evidence_excerpt":"On November 7, 2023, Aconcagua Bio, Inc. (“Aconcagua”), a wholly-owned subsidiary of Structure Therapeutics Inc. (the “Company”), entered into a collaboration agreement (the “Aconcagua-Schrödinger Agreement”) with Schrödinger, Inc. (“Schrödinger”) to discover and develop novel, small molecule modulators of a specific target.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923118241/0001104659-23-118241-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Schrödinger, Inc."},{"label":"Value","value":"up to an aggregate of $89.0 million"},{"label":"Effective","value":"2023-11-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}